Search

for
Search:

GlossaryCetuximab

monoclonal antibody used to treat certain cancers by targeting EGFR

Cetuximab, also known by the brand name Erbitux, is a monoclonal antibody used in cancer treatment. It works by targeting the epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting their growth and survival. This drug is commonly used to treat certain types of head, neck, and colorectal cancers.

Related Terms

Sort by

Research

30 / 1000+ results

research Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation

42 citations , January 2008 in “Clinical colorectal cancer”

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer

35 citations , May 2008 in “Journal of Clinical Oncology”

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

research Cetuximab-Associated Elongation of the Eyelashes

30 citations , August 2010 in “American Journal of Clinical Dermatology”

Cetuximab can cause eyelash growth, which is rare but manageable.

research Incidence and management of cutaneous toxicities associated with cetuximab

30 citations , March 2007 in “Expert opinion on drug safety”

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

research Cetuximab-induced hypertrichosis of the scalp and eyelashes

12 citations , February 2010 in “Journal of The American Academy of Dermatology”

A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.

research Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment

3 citations , August 2019 in “Journal of Cancer Research and Therapeutics”

Cetuximab can cause unusual hair growth and hair loss.

research Cetuximab Induced Hidrocystomas: A Case Report

August 2020 in “SKIN The Journal of Cutaneous Medicine”

Cetuximab can cause skin cysts after acne-like eruptions.

research Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab

1 citations , June 2018 in “Dermatologic Surgery”

BAYONET Trial: Staged Combination With Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-Mutant Metastatic Colorectal Cancer

research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

June 2024 in “ESMO Gastrointestinal Oncology”

The combination treatment showed a higher response rate but no significant survival benefits.

research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.

91 citations , April 2006 in “PubMed”

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

research Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy

17 citations , January 2010 in “Acta Dermato Venereologica”

EGFR inhibitors can cause yellowish skin eruptions.

research Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients

9 citations , October 2015 in “Journal of Cutaneous Pathology”

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers

3 citations , January 2011 in “Annals of Dermatology”

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

PRIDE Complex: Papulopustules, Paronychia, Hair Growth Abnormalities, Itching, and Dryness Due to EGFR Inhibitors

research PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)

August 2025 in “JEADV Clinical Practice”

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers

research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique

January 2011

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

research Perspectives in Head and Neck Medical Oncology

4 citations , January 2018 in “Cancer treatment and research”

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

research The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

54 citations , September 2012 in “Acta ophthalmologica”

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

research Malignant epithelial tumors: Part II. Therapy and prevention

5 citations , January 2013 in “Journal der Deutschen Dermatologischen Gesellschaft”

The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.

research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer

February 2026 in “Oncology Reviews”

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

research 179 Eyebrow Hair Transplantation in Frontal Fibrosing Alopecia: Warning About the Short- and Long-Term Results

September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology”

Eyebrow hair transplants in patients with frontal fibrosing alopecia may look good at first but often lose the new hair after a few years.

research Redox-Modulatory and MET-Inhibitory Triad: Synergistic Cytotoxicity of L-cysteine, NAC, and MET Inhibition in Cervical Cancer Cells

November 2025 in “Eurasian journal of applied biotechnology”

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

research PC-SPES Studies Promising, But Manufacturer Shuts Down

September 2002 in “Oncology Times”

Promising cancer treatments were found, but the manufacturer closed.

research Sacituzumab Govitecan-Hziy (Trodelvy™)

3 citations , April 2021 in “Oncology Times”

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

research Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report

June 2019 in “International journal of dermatology and venereology”

A man developed skin issues from cancer medication, which improved with specific treatments.

research Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia

20 citations , July 2013 in “PLoS ONE”

Targeting EGFR may help reduce hair loss from chemotherapy.

research Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma

June 2025 in “BMJ Case Reports”

Axitinib treatment turned a man's grey hair back to black.

Resolution of Advanced Conjunctival Squamous Cell Carcinoma with Cemiplimab Immunotherapy, IFNα-2b, and Retinoic Acid Treatment Over 2 Years of Follow-Up

research Resolution of advanced conjunctival squamous cell carcinoma with cemiplimab immunotherapy, IFNα-2b, and retinoic acid treatment over 2 years of follow-up

April 2024 in “Canadian Journal of Ophthalmology”

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

research Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors

12 citations , January 2014 in “Journal of international medical research”

Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.

research Dual blockage of P-cadherin and c-Met synergistically inhibits the growth of head and neck cancer

May 2025 in “Cellular Oncology”

Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.

research Doxetaxel: new indication. Prostate cancer: a few more weeks.

February 2006 in “PubMed”

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.